Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.59 |
| ▸ | SIK1 | P57059 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.49 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 7/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16371246 | 0.90 | BTK (0.62) | BTKSIK1MELKSIK2SIK3 | |
| SCHEMBL17837341 | 0.87 | BTK (0.79) | BTKFGFR1CTSCEGFRJAK3 | |
| SCHEMBL16370525 | 0.85 | BTK (0.58) | BTKSIK1MELKSIK2SIK3 | |
| SCHEMBL19441998 | 0.81 | BTK (0.58) | BTKSIK1MELKSIK2SIK3 | |
| SCHEMBL17856985 | 0.80 | BTK (0.68) | BTKFGFR1CTSCEGFRJAK3 | |
| SCHEMBL17837360 | 0.80 | BTK (0.61) | BTKSIK1MELKSIK2SIK3 | |
| SCHEMBL17837342 | 0.80 | BTK (0.81) | BTKFGFR1CTSCEGFRJAK3 | |
| SCHEMBL17857021 | 0.79 | BTK (0.66) | BTKSIK1MELKSIK2SIK3 | |
| SCHEMBL19440565 | 0.79 | BTK (0.68) | BTKSIK1MELKSIK2SIK3 | |
| SCHEMBL17857015 | 0.79 | BTK (0.66) | BTKFGFR1CTSCEGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331037-B2 | Pyrimidines as EGFR-inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | BTK 137/4885SIK1 1674/4885MELK 389/4885 |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | BTK 104/4885SIK1 1898/4885MELK 375/4885 |
| US-12331037-B2 | Pyrimidines as EGFR-inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | BTK 111/4885SIK1 1699/4885MELK 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.